We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+88.59%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.65B
AUM Growth
+$539M
Cap. Flow
+$95.2M
Cap. Flow %
5.75%
Top 10 Hldgs %
47.9%
Holding
83
New
24
Increased
15
Reduced
20
Closed
14

Top Buys

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$46.6M
2
TNGX icon
Tango Therapeutics
TNGX
+$28M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$27.9M
4
IMVT icon
Immunovant
IMVT
+$24.5M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$20.6M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$57M
2
ARVN icon
Arvinas
ARVN
+$47.5M
3
DYN icon
Dyne Therapeutics
DYN
+$21.8M
4
VSTM icon
Verastem
VSTM
+$20.9M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$19.9M

Sector Composition

Rank Sector Weight
1 Healthcare 90.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TYRA icon
51
Tyra Biosciences
TYRA
$1.84B
$5.52M 0.33%
+210,000
New +$3.86M
ELVN icon
52
Enliven Therapeutics
ELVN
$3.84B
$5.24M 0.32%
340,000
– –
IMMX icon
53
Immix Biopharma
IMMX
$601M
$5.23M 0.32%
+1,000,000
New +$4.12M
CNTA
54
DELISTED
Centessa Pharmaceuticals
CNTA
$5M 0.3%
200,000
-325,000
-62% -$8.23M
NGNE icon
55
Neurogene
NGNE
$663M
$4.02M 0.24%
+195,000
New +$4.85M
IBIO icon
56
iBio
IBIO
$69.1M
$3.86M 0.23%
+2,000,000
New +$2.73M
CRVS icon
57
Corvus Pharmaceuticals
CRVS
$1.12B
$3.85M 0.23%
+500,000
New +$3.94M
ORIC icon
58
Oric Pharmaceuticals
ORIC
$1.23B
$3.68M 0.22%
+450,000
New +$5.18M
DAWN
59
DELISTED
Day One Biopharmaceuticals
DAWN
$2.8M 0.17%
+300,000
New +$2.51M
PHVS icon
60
Pharvaris
PHVS
$2.35B
$2.77M 0.17%
100,000
-50,000
-33% -$1.2M
UNCY icon
61
Unicycive Therapeutics
UNCY
$135M
$2.73M 0.17%
473,563
– –
GUTS icon
62
Fractyl Health
GUTS
$115M
$2.42M 0.15%
1,100,000
+600,000
+120% +$966K
PTN
63
Palatin Technologies
PTN
$13.7M
$2.15M 0.13%
+140,000
New +$2.6M
ACRS icon
64
Aclaris Therapeutics
ACRS
$744M
$1.81M 0.11%
600,000
-900,000
-60% -$2.27M
VOR icon
65
Vor Biopharma
VOR
$1.08B
$1.31M 0.08%
+100,000
New +$1.86M
MREO
66
Mereo BioPharma
MREO
$48.2M
$771K 0.05%
1,850,000
+1,350,000
+270% +$2.57M
SEPN
67
Septerna Inc
SEPN
$1.53B
$657K 0.04%
23,548
-60,000
-72% -$1.43M
DBVT
68
DBV Technologies
DBVT
$799M
$479K 0.03%
+25,000
New +$391K
NUVB.WS
69
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$22K ﹤0.01%
66,666
– –
AKRO
70
DELISTED
Akero Therapeutics
AKRO
– –
-1,200,000
Closed -$57M
ALEC icon
71
CALL
Alector
ALEC
$169M
– –
-500,000
Closed -$1.48M
ARVN icon
72
Arvinas
ARVN
$529M
– –
-5,575,000
Closed -$47.5M
ATXS
73
DELISTED
Astria Therapeutics
ATXS
– –
-500,000
Closed -$3.64M
COGT icon
74
Cogent Biosciences
COGT
$6.95B
– –
-500,000
Closed -$7.18M
ESPR
75
DELISTED
Esperion Therapeutics
ESPR
– –
-750,000
Closed -$1.99M
1 2
3
4

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q4 2025 Portfolio in Review

As of Q4 2025, Logos Global Management held 83 positions worth $1.65B, up 48% from $1.12B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Logos Global Management deployed $95.2M of net new capital in Q4 2025, opening 24 new positions and adding to 15 existing holdings. Its largest new stake was MoonLake Immunotherapeutics: 1,750,000 shares worth $23.1M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 91% a quarter earlier.

On the sell side, the largest reduction was Dyne Therapeutics, an estimated $21.8M trimmed.

  • Logos Global Management's largest Q4 2025 buy was MoonLake Immunotherapeutics: 1,750,000 shares worth $23.1M.
  • Logos Global Management added most to Praxis Precision Medicines in Q4 2025, an estimated $46.6M increase.
  • Logos Global Management's biggest Q4 2025 reduction was Dyne Therapeutics, cutting an estimated $21.8M.
  • Logos Global Management fully exited Akero Therapeutics in Q4 2025, selling an estimated $57M.
  • Logos Global Management's ten largest holdings make up 48% of its $1.65B portfolio in Q4 2025.
  • Logos Global Management opened 24 new positions and closed 14 in Q4 2025.
  • Logos Global Management's portfolio value rose 48% quarter-over-quarter to $1.65B.

Based on Logos Global Management's 13F filing for Q4 2025, filed 17 Feb 2026.